Trending...
- The Parent Tap Airs Raw Discussion on Hidden Youth Mental Health Struggles and Loss
- HSS Medical Supply Celebrates One-Year Anniversary of Its Top Performing Sales Team
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
Preliminary framework pairs NeoPathology's clinical network with Qscription's enterprise integration and U.S. operations capability.
MILWAUKEE - Arizonar -- Qscription Technologies Inc., a U.S. market-entry and clinical AI integration company, and NEOPATHOLOGY CORP., a biotechnology research and clinical diagnostic development company, today announced a Memorandum of Understanding (MOU).
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Arizonar
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Arizonar
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Arizonar
- Solo Attorneys Face a Growing Challenge
- Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
- AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
- UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
- Arizona: Applications Open for Upcoming Vacancy on the Yuma County Superior Court
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Arizonar
- Arizona: Governor Katie Hobbs Announces Appointment of Dawn R. Walton and Nicole P. Savel to Pima County Superior Court
- Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
- AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
- DayPass llega a ChatGPT y Claude
- DayPass launches in ChatGPT and Claude
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Source: Qscription Technologies Inc
0 Comments
Latest on The Arizonar
- Mesa Music Festival Rocks Downtown with P.O.D. and Music Industry Heavyweights
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
- PODS Tucson, 94.9 MIXfm, El Encantada, Radiology Ltd. All help Sister José Women's Center
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
- Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
- Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Governor Katie Hobbs and Arizona Tribal Leaders Oppose Federal Government's Rollback of Cultural and Historic Preservation Protections
- MyFairClaim Relaunches Online Diminished Value Appraisals for Drivers in All 50 States and D.C
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
- Mesa Public Library Hosts Donate Day
- Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
- Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
- 6 Questions to Ask Your Dentist About AI-Assisted X-Rays, From Tempe's Cereus Dental Care
- The Parent Tap Airs Raw Discussion on Hidden Youth Mental Health Struggles and Loss